Other

University of Medicine and Dentistry of New Jersey

Bo Qiu

Stanley Stein

Guobao Zhang

Michael Brunner

Leonard Sigal

Michael Katz

Patrick J Sinko

Xiaoping Zhang

Tamara Minko

Gregory Charles Williams

Michael Leibowitz

Goubao Zhang

Shahrair Pooyan

Seong Hee Park

Pankaj Paranjpe

Srinivasan Ramanathan

The invention is directed to pharmaceutical compositions and methods for delivery of a therapeutic or diagnostic agent from one bodily compartment to one or more other bodily compartment by administering one of the following conjugates: a polymer having multiple functional groups at least one of which is covalently bound to a therapeutic or diagnostic agent, and at least one cell uptake promoter covalently bound to the therapeutic or diagnostic agent; or a polymer and at least one cell uptake promoter bound thereto; the polymer further comprising multiple functional groups at least one of which is covalently bound a therapeutic or diagnostic agent.

Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents

Immunologically invisible carrier molecules connect a plurality of copies of an immunologically active molecule in an immunologic assay.

Borellia burgdorferi epitope peptides

A novel compound comprising an immunologically invisible polyethylene glycol copolymer is used to carry one or more immunologically reactive substances. The novel compounds may be used as part of kits for immunological assays.

Immunological test kit comprising an immunologically invisible peg copolymer conjugated to one or more immunologically reactive substances

This invention pertains to disulfide-linked conjugates of therapeutic agents containing at least one thioamide group with polymer comprising at least one thiol group, so as to provide a controlled release pharmaceutical composition for administration to animals for the prophylaxis or treatment of various conditions or diseases. The therapeutic agent conjugate may comprise an inactive or weakly active prodrug form which may be converted into the original therapeutic compound by the natural action of reducing agents in vivo. The composition may comprise a mixture of polymers each with a different thioamide-containing agent attached, or a polymer conjugated with a mixture of thioamide-containing agents. Modified properties of the therapeutic compound potentially provided by the polymer itself, as well as by other compounds also appended to the polymer, include but are not limited to greater water solubility, longer in-vivo half-life (due to larger size of the conjugate), slower release from a sustained-release depot (due to larger size of the conjugate), better oral bioavailability and tissue-specific targeting.

Controlled release of thioamide moiety-containing therapeutic agents

Growing community of inventors

East Brunswick, NJ, United States of America

Bo Qiu